BDXHealthcare · Medical Instruments & SuppliesThe 16 Wall Street analysts covering Becton, Dickinson & Co. hold a median 12-month price target of $198 — -5.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 4 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Becton, Dickinson & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (42): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (5): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −5.6% from it.
Of the 20 most recent actions, 7 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Underweight | $165 |
| 31 Aug 2026 | B of A Securities | Maintains | Neutral | $185 → $200 |
| 31 Aug 2026 | B of A Securities | Maintains | Neutral | — |
| 13 Aug 2026 | RBC Capital | Maintains | Sector Perform | $180 → $190 |
| 13 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 Aug 2026 | Citigroup | Maintains | Buy | $198 → $204 |
| 7 Aug 2026 | Citigroup | Maintains | Buy | — |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | — |
| 7 Aug 2026 | Piper Sandler | Maintains | Neutral | $161 → $175 |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | — |
| 7 Aug 2026 | RBC Capital | Maintains | Sector Perform | $175 → $180 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $161 → $170 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 5 Aug 2026 | TD Cowen | Maintains | Hold | — |
| 5 Aug 2026 | TD Cowen | Maintains | Hold | $163 → $182 |
| 28 July 2026 | UBS | Initiates | Buy | — |
| 28 July 2026 | UBS | Initiates | Buy | $190 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $190 → $180 |
| 11 May 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BDX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Becton, Dickinson & Co. returned +52.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 16% of US stocks
Cheaper than 47% of US stocks
Cheaper than 39% of US stocks
Cheaper than 33% of US stocks
Higher than 41% of US stocks
Higher than 15% of US stocks
Higher than 57% of US stocks
Higher than 73% of US stocks
Higher than 58% of US stocks
Higher than 56% of US stocks
Higher than 73% of US stocks
Higher than 80% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Becton, Dickinson & Co. has a market value of $54.0B and an enterprise value of $70.1B.
Revenue in the twelve months to 30 June 2026: $20.8B. The latest quarter grew 5.4% year on year.
Net income over the same four quarters: $941.0M, a 4.5% net margin.
Free cash flow in the twelve months to 30 June 2026: $2.5B, after $728.0M of capital spending.
Becton, Dickinson & Co. spent $1.2B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 46.1×; forward P/E: 14.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.12%, paying out 72% of earnings.
Becton, Dickinson & Co. employs 72,000 people — $289K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Becton, Dickinson & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BD announced that Bridget Bagnato has been appointed worldwide president of its Peripheral Intervention business unit, effective November 16.
Why it matters — The appointment marks a leadership change in one of BD’s business units.
BD enters its Q4 earnings report with expectations for higher profits despite lower revenues. The excerpt cites strength in Interventional, Medical Essentials and Biologics.
Why it matters — The stated expectations and segment strengths provide context for BDX watchers ahead of its Q4 results.
The article previews Becton Dickinson’s Q4 earnings, noting that it reviews projections for key metrics alongside Wall Street’s revenue and earnings estimates for the quarter ended September 2026.
Why it matters — The additional metric projections may give BDX watchers a broader view of expectations for the quarter beyond headline estimates.
BD launched its Liverty TIPS Stent Graft in the United States. The device is described as offering greater precision and flexibility in portal hypertension treatment.
Why it matters — The U.S. launch expands BD's offerings for portal hypertension treatment.
Emerson is expected to extend its dividend-growth streak to 70 years, with a projected annual dividend increase of 6.3–8.1%, supported by its business transformation and forecast adjusted EPS growth. The article says most long-term dividend payers are expected to announce mid-single-digit increases, while several may exceed 10%.
Why it matters — The item concerns dividend trends and Emerson rather than BDX, so it provides broader industry context but no company-specific BDX update.
The 16 Wall Street analysts covering Becton, Dickinson & Co. have a median 12-month price target of $198, with estimates ranging from $165 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Becton, Dickinson & Co., 8 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Becton, Dickinson & Co. 96 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Becton, Dickinson & Co. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies -5.6% from the last close, and Ticker Nerd's factor model ranks Becton, Dickinson & Co. 96 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Becton, Dickinson & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $165 to $225 over the next 12 months.
Becton, Dickinson & Co. returned +52.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices.
The most recent item we track (PRNewsWire, 4 Nov 2026): "BD Names Bridget Bagnato Worldwide President of Peripheral Intervention". BD announced that Bridget Bagnato has been appointed worldwide president of its Peripheral Intervention business unit, effective November 16.
Becton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells a broad range of products used across healthcare and life sciences. Becton, Dickinson and Company serves hospitals, physicians, clinical laboratories, researchers, and public health organizations with medical supplies, diagnostic systems, laboratory equipment, and interventional devices. Its current business centers on medical essentials, connected care, biopharma systems, and interventional products, supporting workflows such as specimen handling, medication delivery, infection prevention, vascular access, and surgical procedures. The company’s portfolio also includes tools and technologies used in drug delivery, patient safety, and clinical research. Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company plays an important role in enabling medical discovery, improving care delivery, and supporting routine operations in healthcare settings worldwide.
CEO Mr. Thomas E. Polen Jr. · 72,000 employees · United States · https://www.bd.com
